---
schema_version: "secwatch.filing_event.v1"
accession: "0001140361-26-000904"
form_type: "8-K"
ticker: "BNGO"
cik: "0001411690"
company_name: "Bionano Genomics, Inc."
filed_at: "2026-01-12T23:59:59+00:00"
generated_at: "2026-05-16T10:49:19.876253+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.5
calibrated_materiality_score: 0.5
confidence: "medium"
source: SEC EDGAR
---

# Bionano reports preliminary Q4/FY 2025 revenue down 2-8% YoY; cash $29.6M

## Summary
- Total Q4 revenue $7.8-8.0M, down 2-4% YoY; full-year $28.4-28.6M, down 7-8%.
- Installed 9 new OGM systems in Q4, 32 in FY; installed base at 387 systems at year-end.
- Cash, equivalents and restricted investments $29.6M as of Dec 31, 2025 ($10.3M restricted).
- Nanochannel array flowcells sold: 7,554 in Q4, 30,171 for full year 2025.
- Preliminary unaudited results; subject to change after year-end close and audit.

## SEC filing metadata
- accession: 0001140361-26-000904
- form_type: 8-K
- ticker: BNGO
- cik: 0001411690
- company_name: Bionano Genomics, Inc.
- filed_at: 2026-01-12T23:59:59+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.5
- calibrated_materiality_score: 0.5
- confidence: medium
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1411690/000114036126000904/0001140361-26-000904-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1411690/000114036126000904/ef20062688_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001140361-26-000904
- JSON: https://secwatch.observer/filing/0001140361-26-000904.json
- Plain text: https://secwatch.observer/filing/0001140361-26-000904.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.